1-O-acetyl-2,3,5-tri-O-benzoyl-3-C-ethynyl-D-ribofuranose | 182825-17-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-O-acetyl-2,3,5-tri-O-benzoyl-3-C-ethynyl-D-ribofuranose
• 英文别名: [(2R,3R,4R)-5-acetyloxy-3,4-dibenzoyloxy-3-ethynyloxolan-2-yl]methyl benzoate
• CAS: 182825-17-8
• 化学式: C₃₀H₂₄O₉
• 分子量: 528.515
• InChiKey: ZCNJZCTTWIADED-XWQKXFBKSA-N

物化性质

• 沸点：
  630.0±55.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  39
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  114
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  1-O-acetyl-2,3,5-tri-O-benzoyl-3-C-ethynyl-D-ribofuranose 在 吡啶 、 sodium methylate 、 四氯化锡 、 六甲基二硅氮烷 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 9-(3-C-ethynyl-β-D-ribofuranosyl)guanine
  参考文献：
  名称：

  Nucleosides and Nucleotides. 158. 1-(3-C-Ethynyl-β-d-ribo-pentofuranosyl)- cytosine, 1-(3-C-Ethynyl-β-d-ribo-pentofuranosyl)uracil, and Their Nucleobase Analogues as New Potential Multifunctional Antitumor Nucleosides with a Broad Spectrum of Activity

  摘要：

  We previously designed 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil (EUrd) as a potential multifunctional antitumor nucleoside antimetabolite. It showed a potent and broad spectrum of antitumor activity against various human tumor cells in vitro and in vivo. To determine the structure-activity relationship, various nucleobase analogues of EUrd, such as 5-fluorouracil, thymine, cytosine, 5-fluorocytosine, adenine, and guanine derivatives, were synthesized by condensation of 1-O-acetyl-2,3,5-tri-O-benzoyl-3-C-ethynyl-alpha,beta-D-ribo-pentofuranose (6) and the corresponding pertrimethylsilylated nucleobases in the presence of SnCl4 or TIMSOTf as a Lewis acid in CH3CN followed by debenzoylation. The in vitro tumor cell growth inhibitory activity of these 3'-C-ethynyl nucleosides against mouse leukemia L1210 and human nasopharyngeal KB cells showed that 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd) and EUrd were the most potent inhibitors in the series, with IC50 values for L1210 cells of 0.016 and 0.13 mu M and for KB cells of 0.028 and 0.029 mu M, respectively. 5-Fluorocytosine, 5-fluorouracil, and adenine nucleosides showed much lower activity, with IC50 values of 0.4-2.5 mu M, while thymine and guanine nucleosides did not exhibit any activity up to 300 mu M. We next evaluated the tumor cell growth inhibitory activity of ECyd and EUrd against 36 human tumor cell lines in vitro and found that they were highly effective against these cell lines with IC50 values in the nanomolar to micromolar range. These nucleosides have a similar inhibitory spectrum. The in vivo antitumor activities of ECyd and EUrd were compared to that of 5-fluorouracil against 11 human tumor xenografts including three stomach, three colon, two pancreas, one renal, one breast, and one bile duct cancers. ECyd and EUrd showed a potent tumor inhibition ratio (73-92% inhibition relative to the control) in 9 of 11 and 8 of 11 human tumors, respectively, when administered intravenously for 10 consecutive days at doses of 0.25 and 2.0 mg/kg, respectively, while 5-fluorouracil showed potent inhibitory activity against only one tumor. Such excellent antitumor activity suggests that ECyd and EUrd are worth evaluating further for use in the treatment of human cancers.

  DOI：

  10.1021/jm960537g
• 作为产物：
  描述：

  5-O-(tert-butyldimethylsilyl)-1,2-O-isopropylidene-α-D-erythro-pentofuranos-3-ulose 在 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 正丁基锂 、 硫酸 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 溶剂黄146 为溶剂， 生成 1-O-acetyl-2,3,5-tri-O-benzoyl-3-C-ethynyl-D-ribofuranose
  参考文献：
  名称：

  Nucleosides and nucleotides. 152. 1-(3-C-Ethynyl-β-D-ribo-pentofuranosyl)uracil as a broad spectrum antitumor nucleoside

  摘要：

  1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)uracil (EUrd) has been designed as a potential multifunctional antitumor nucleoside antimetabolite. EUrd was synthesized by condensation of 1-O-acetyl-2,3,5-tri-O-benzoyl-3-C-ethynyl-alpha,beta-D-ribo-pentofuranose (6) and bis(trimethylsilyl)uracil in the presence of trimethylsilyl triflate in CH3CN in good yield, followed by debenzoylation with NH3/MeOH. In vitro tumor cell growth inhibitory activity of EUrd against 14 human solid tumor cell lines was compared with 5-fluorouridine (FUrd), 2'-deoxy-5-fluorouridine (FdUrd), and 5-fluorouracil (5-FU) as positive controls. EUrd was a quite potent tumor cell growth inhibitor against almost ail the tumor cell lines examined in this study except for human pancreas PANC-1 cells, and the potency of EUrd is about 6 to 650 times stronger than that of 5-FU and comparable to that of FUrd and FdUrd. EUrd showed also potent antitumor activity against human tumors as xenografts in nude mice when given in a daily intravenous dose of 2 mg/kg on consecutive days. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00339-3

文献信息

• Synthesis and Cytotoxicity of 4-Amino-5-oxopyrido[2,3-<i>d</i>]pyrimidine Nucleosides
  作者：Jean-Luc Girardet、Esmir Gunic、Cathey Esler、Dariusz Cieslak、Zbigniew Pietrzkowski、Guangyi Wang

  DOI：10.1021/jm000073t

  日期：2000.10.1

  1-O-acetylated pentose sugar derivatives were condensed with silylated 4-amino-5-oxopyrido[2,3-d]pyrimidine, followed by protection, to afford a series of 4-amino-5-oxopyrido[2, 3-d]pyrimidine nucleosides. Further derivatizations provided an additional group of pyrido[2,3-d]pyrimidine nucleosides. These nucleosides were evaluated for in vitro cytotoxicity to human prostate cancer (HTB-81) and mouse melanoma

  许多核苷类似物已被临床用作抗癌药物或已在临床研究中进行了评估，而新的核苷类似物继续显示出希望。在本文中，我们报告了一系列新的吡啶并[2,3-d]嘧啶核苷的合成和细胞毒性。通过两个步骤将2-氨基-3-氰基-4-甲氧基吡啶转化为4-氨基-5-氧代吡啶并[2,3-d]嘧啶。将各种1-O-乙酰化戊糖衍生物与甲硅烷基化的4-氨基-5-氧代吡啶并[2,3-d]嘧啶缩合，然后进行保护，得到一系列的4-氨基-5-氧代吡啶并[2， 3-d]嘧啶核苷。进一步的衍生化提供了另外的吡啶基[2，3-d]嘧啶核苷基团。评估了这些核苷对人前列腺癌（HTB-81）和小鼠黑素瘤（B16）细胞以及正常人成纤维细胞（NHF）的体外细胞毒性。许多化合物（1a，b，2a-c，f，3f + 4d）对癌细胞具有明显的细胞毒性，其中4-氨基-5-氧代-8-（β-D-呋喃呋喃糖基）吡啶并[2,3- d]嘧啶（1b）是所有类型细胞中最有效的增殖抑制剂（EC（50）：0
• Synthesis of a 3′-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides
  作者：Fabian Hulpia、Sam Noppen、Dominique Schols、Graciela Andrei、Robert Snoeck、Sandra Liekens、Peter Vervaeke、Serge Van Calenbergh

  DOI：10.1016/j.ejmech.2018.07.062

  日期：2018.9

  A focused nucleoside library was constructed around a 3′-C-ethynyl-d-ribofuranose sugar scaffold, which was coupled to variously modified purine nucleobases. The resulting nucleosides were probed for their ability to inhibit tumor cell proliferation, as well as for their activity against a panel of relevant human viruses. While C6-aryl substituted purine nucleosides were found to be weakly active,

  聚焦核苷文库构建周围3'- Ç乙炔基d -ribofuranose糖支架，其耦合到各种修饰的嘌呤核碱基。探测所得核苷抑制肿瘤细胞增殖的能力，以及它们对一组相关人类病毒的活性。虽然发现C6-芳基取代的嘌呤核苷的活性较弱，但一些C7取代的7-脱氮嘌呤核苷却具有很强的抗增殖活性。在NCI-60肿瘤细胞系面板中评估了它们的活性谱，表明其对几种实体肿瘤衍生的细胞系的活性。模拟32在转移性乳腺肿瘤（MDA-MB-231-LM2）异种移植模型中评估了配备了7-脱氮7-氯6-氨基嘌呤9-基碱基的脱氧核糖核酸。BLI分析显示，它既抑制肿瘤生长，又减少了肺转移的形成。双十二碳核苷类似物66显示出针对hCMV的有趣活性。这些结果突出了重组已知糖和核碱基基序作为发现新型抗病毒或抗肿瘤剂的文库设计策略的潜在优势。
• SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS
  申请人：Srivastava Suresh C.

  公开号：US20120149888A1

  公开（公告）日：2012-06-14

  The present invention relates to synthesis, purification and methods to obtain high purity novel 2′-arabino-O-methyl nucleosides and the corresponding phosphoramidites of various arabinonucleoside bases and introduction of such units into defined sequence synthetic DNA and RNA. Various synthetic oligonucleotides, such as HIV integrase inhibitor 14-mer and thrombin binding oligonucleotide, thrombin-1, bearing ara-2′-omethyl modification have been synthesized. It is anticipated the oligonucleotides incorporating these monomers will exhibit biological activities related to antisense approach approach, design of better SiRNA's, diagnostic agents. Similarly, it is anticipated that oligonucleotides incorporating such novel nucleosides will be useful to develop therapeutic candidates designing stable G-quadruplexes and Aptamers for oligonucleotide structure, folding topology, evaluation of biochemical properties and design and develop as therapeutic agents. It is further anticipated that the nucleosides, phosphates and triphosphates of this invention could develop as therapeutic agents.

  本发明涉及合成、纯化和获取高纯度新型2'-阿拉伯核苷-O-甲基核苷和各种阿拉伯核苷基的相应磷酰胺酯的方法，并将这些单元引入到定义的序列合成DNA和RNA中。已合成了各种合成寡核苷酸，例如HIV整合酶抑制剂14-mer和凝血酶结合寡核苷酸，凝血酶-1，带有ara-2'-omethyl修饰。预计包含这些单体的寡核苷酸将展示与反义方法、更好的SiRNA设计、诊断剂相关的生物学活性。同样，预计包含这些新型核苷的寡核苷酸将有助于开发稳定的G四链体和寡核苷酸结构的Aptamers，用于寡核苷酸结构、折叠拓扑、生化特性的评估和设计和开发为治疗剂。进一步预计，本发明的核苷、磷酸盐和三磷酸盐可作为治疗剂开发。
• 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：EP0747389A1

  公开（公告）日：1996-12-11

  The invention relates to a 3'-substituted nucleoside derivative represented by the following general formula (1): wherein B means a nucleic acid base which may have a substituent, Z represents a lower alkynyl or lower alkenyl group which may be substituted by a group represented by the formula: in which Ra, Rb and Rc are individually a lower alkyl group or a phenyl group, or an oxiranyl group which may have at least one lower alkyl group, R1 and R2 individually represent H or an ester-forming residue capable of easily leaving in a living body, and R3 is H, a mono- or polyphosphoric acid residue, or an ester-forming residue capable of easily leaving in a living body, with the proviso that the sugar moiety is ribose, or a pharmaceutically acceptable salt thereof. The 3'-substituted nucleoside derivative according to the invention has an excellent antitumor activity and is hence useful for treatment for and prevention of cancers.

  本发明涉及由以下通式（1）代表的 3'-取代的核苷衍生物： 其中 B 表示可具有取代基的核酸碱基，Z 表示可被式中代表的基团取代的低级炔基或低级烯基： 其中，Ra、Rb 和 Rc 分别为低级烷基或苯基，或可具有至少一个低级烷基的环氧乙烷基，R1 和 R2 分别代表 H 或可容易地留在生物体内的酯形成残基，R3 为 H、单磷酸或多磷酸残基或可容易地留在生物体内的酯形成残基，但糖基为核糖或其药学上可接受的盐。根据本发明，3'-取代的核苷衍生物具有优异的抗肿瘤活性，因此可用于治疗和预防癌症。
• Nucleosides and nucleotides. Part 212: Practical large-scale synthesis of 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)cytosine (ECyd), a potent antitumor nucleoside. Isobutyryloxy group as an efficient anomeric leaving group in the Vorbrüggen glycosylation reaction
  作者：Makoto Nomura、Tsutomu Sato、Masato Washinosu、Motoaki Tanaka、Tetsuji Asao、Satoshi Shuto、Akira Matsuda

  DOI：10.1016/s0040-4020(01)01249-2

  日期：2002.2

  A practical synthetic route to the antitumor nucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, 1) from 1,2-O-isopropylidene-D-xylofuranose (3) has been developed. Since most of the compounds were obtained as crystals, the target ECyd was prepared without any chromatographic purification in 31% overall yield from compound 3. The isobutyryloxy group was found to be an effective leaving group at the anomeric position of the 3-beta-C-ethynyl glycosyl donors in the key Vorbruggen glycosylation reaction. Using a similar procedure without chromatographic purification, the uracil congener EUrd [1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil (2), which also has a potent antitumor effect, was synthesized from 3 in 39% overall yield. (C) 2002 Elsevier Science Ltd. All rights reserved.